The DOI matches its Crossref record; 51 of the 56 references it cites were found in a registry or an index; 28 of the 57 sources its claims cite were checked for support.
The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System
Open accessAbstract
Context: Adrenal insufficiency (AI) is a life-threatening condition complicating heterogeneous disorders across various disciplines, with challenging diagnosis and a notable drug-induced component. Objective: This work aimed to describe the spectrum of drug-induced AI through adverse drug event reports received by the US Food and Drug Administration (FDA). Methods: A retrospective disproportionality analysis reporting trends of drug-induced AI was conducted on the FDA Adverse Event Reporting System (FAERS) (> 15 000 000 reports since 2004). AE reports were extracted from FAERS over the past 2 decades. Interventions included cases containing any of the preferred terms in the Medical Dictionary for Regulatory Activities describing AI, and signals of disproportionate reporting for drugs recorded in 10 or more cases as primary suspect. Results: We identified 8496 cases of AI: 97.5% serious, 41.1% requiring hospitalization. AI showed an exponential increase throughout the years, with 5282 (62.2%) cases in 2015 to 2020. We identified 56 compounds associated with substantial disproportionality: glucocorticoids (N = 1971), monoclonal antibodies (N = 1644, of which N = 1330 were associated with immune checkpoint inhibitors—ICIs), hormone therapy (N = 291), anti-infectives (N = 252), drugs for hypercortisolism or adrenocortical cancer diagnosis/treatment (N = 169), and protein kinase inhibitors (N = 138). Cases of AI by glucocorticoids were stable in each 5-year period (22%-27%), whereas those by monoclonal antibodies, largely ICIs, peaked from 13% in 2010 to 2015 to 33% in 2015 to 2020. Conclusion: We provide a comprehensive insight into the evolution of drug-induced AI, highlighting the heterogeneous spectrum of culprit drug classes and the emerging increased reporting of ICIs. We claim for the urgent identification of predictive factors for drug-induced AI, and the establishment of screening and educational protocols for patients and caregivers.
Overview
CoChat Summary
TL;DR
This FAERS disproportionality analysis identified 8,496 drug-induced adrenal insufficiency (AI) cases, mostly serious, with glucocorticoids reported stably and monoclonal antibodies/immune checkpoint inhibitors rising sharply in 2015-2020. It describes a heterogeneous culprit drug spectrum and calls for screening, education, and identification of predictive factors.
Key findings
- Among 10,400,290 retained FAERS reports, 8,496 AI cases were identified; 97.5% were serious, 41.1% required hospitalization, and 5,282 (62.2%) occurred in 2015-2020, showing an exponential increase over time.
- 56 compounds had disproportionate reporting: glucocorticoids (N = 1971), monoclonal antibodies (N = 1644; ICIs N = 1330), hormone therapy (N = 291), anti-infectives (N = 252), drugs for hypercortisolism/adrenocortical cancer (N = 169), and protein kinase inhibitors (N = 138).
- Glucocorticoid-related AI remained stable across 5-year periods (22%-27%), whereas monoclonal antibodies rose from 13% in 2010-2015 to 33% in 2015-2020; ICIs showed a steady increase (N = 433 in 2020).
- In 2015-2020, the most frequently reported drugs were nivolumab (N = 612), pembrolizumab (N = 270), ipilimumab (N = 230), hydrocortisone (N = 206), triamcinolone (N = 152), and fluticasone (N = 150); monoclonal antibody cases included 866 hospitalizations (53%) and 172 deaths (11%), versus 513 (27%) and 69 (3.6%) for glucocorticoids.
Methods
- Retrospective disproportionality analysis of FAERS data up to 2020, after deduplication, retaining 10,400,290 reports; AI cases were identified using MedDRA preferred terms under the high-level term “adrenal cortical hypofunctions,” excluding low-specificity terms, and exposure was restricted to drugs recorded as primary suspect.
- Case/noncase reporting odds ratios (RORs) with 95% CIs were calculated; signals required the lower 95% CI > 1, at least 10 cases, and Bonferroni correction, using R version 4.1.1 and valid percentages for missing data.
Limitations
- The paper states traditional pharmacovigilance limitations: causality cannot be inferred (ROR is not a risk measure), information quality may be incomplete (eg, laboratory/clinical validation), and lack of denominators prevents incidence calculation; increased reporting may reflect missing data before 2010, mandatory trial reporting, greater awareness, and expanding anticancer drug approvals.
- The paper also notes reporting biases over time, including underreporting, stimulated reporting/notoriety bias, the Weber effect, and competition bias; lack of disproportionality should not be interpreted as safety, and patients may receive multiple medications potentially affecting adrenal function, though the analysis was restricted to suspect drugs.
- Evident from the design: FAERS spontaneous reports cannot control for confounders or verify diagnoses, and the findings describe reporting patterns rather than confirmed drug-induced AI risk.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
21 Valid · 1 Not valid · 13 Not checked · 66 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Clinically relevant AI may arise after abrupt or inappropriately managed withdrawal of glucocorticoids, especially in patients taking oral and intra-articular long-acting formulations, high glucocorticoid doses, and long treatment regimens (15, 16).”
§ The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System > Discussion
What the sources say
- Partly supportedcites [15] Laugesen, 2021, Management of endocrine disease: glucocorticoid-induced adrenal insufficiency: replace while we wait for evidence?, Eur J Endocrinol. sourceExperimental — accuracy not yet measured
The Highlights and Dose and duration sections identify oral and intra-articular administration, high doses, and prolonged treatment as risk factors for glucocorticoid-induced adrenal insufficiency. The Occurrence section documents insufficiency during or around cessation, but the Clinical practice section says it remains unclear how often biochemically diagnosed insufficiency causes clinically relevant morbidity. The paper does not establish that abrupt or inappropriately managed withdrawal is the particular trigger, or that the higher-risk formulations are specifically long-acting. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [16] Prete, 2021, Glucocorticoid induced adrenal insufficiency, BMJ. source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Primary AI is related to an immune destruction of the adrenal glands consequent to a hyperstimulation of the immune system due to ICIs mechanism of action.”
§ The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System > Discussion
What the sources say
- Not checked — no full text of the sourcecites [32] Hescot, 2018, Immunotherapy-induced Addison’s disease: a rare, persistent and potentially lethal side-effect, Eur J Cancer. source
- Partly supportedcites [33] Paepegaey, 2017, Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma, J Endocr Soc. sourceExperimental — accuracy not yet measured
The Discussion reports pembrolizumab-associated primary adrenal failure and says positive antiadrenal antibodies confirmed an autoimmune cause in the patient. The paper also says checkpoint inhibitors restore T-cell activity and can cause autoimmune toxicity, but it does not establish immune-system hyperstimulation as the mechanism of adrenal destruction; it says the mechanisms of endocrine toxicity remain unclear. No page numbers are available in our copy. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Conversely, the plausible causative immune-mediated effect of ICIs is largely supported by clinical evidence (3); the nonnegligible proportion of cases with concomitant corticosteroids (19%) could be especially interpreted in the light of treatment of concurrent immune-related adverse events (irAEs).”
§ The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System > Discussion
What the sources say
- Supportedcites [3] Grouthier, 2020, Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis, Oncologist. source
The Results identify 451 reports of ICI-associated primary adrenal insufficiency, including 45 classified as definite. The Discussion says its pathophysiology is not well defined but is likely mediated by ICI-induced autoimmune activation, and describes clinical findings consistent with that possibility. The claim's word “plausible” preserves that uncertainty. (LLM, conf=0.85)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The net increase in reports of AI in patients under ICIs depicted in our study is consistent with the widespread and increasing use of those drugs during recent years (36).”
§ The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System > Discussion
What the sources say
- Partly supportedcites [36] Haslam, 2019, Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs, JAMA Netw Open. sourceExperimental — accuracy not yet measured
The Abstract Findings report a sharp rise in the estimated share of US cancer patients eligible for checkpoint inhibitors from 2011 to 2018, supporting the claim of expanding potential use. But the Limitations section explicitly says the study estimates rather than measures drug uptake, so it does not establish that actual use was widespread and increasing. The increase in adrenal-insufficiency reports is the citing authors’ own finding, not a finding attributed to this source. (LLM, conf=0.86)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Even though treatment regimens, route of administration, potency, dose, duration of glucocorticoid treatment, as well as individual glucocorticoid sensitivity, have been postulated as potential risk factors for glucocorticoid-induced AI, no clear-cut predictive factors of risk of onset and duration of AI before HPA axis recovery have been identified so far (15, 16, 20, 21).”
§ The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System > Discussion
What the sources say
- Supportedcites [15] Laugesen, 2021, Management of endocrine disease: glucocorticoid-induced adrenal insufficiency: replace while we wait for evidence?, Eur J Endocrinol. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
- Not checked — no full text of the sourcecites [16] Prete, 2021, Glucocorticoid induced adrenal insufficiency, BMJ. source
- Not checked — no full text of the sourcecites [20] Berr, 2015, Time to recovery of adrenal function after curative surgery for Cushing’s syndrome depends on etiology, J Clin Endocrinol Metab. source
- Not checked — no full text of the sourcecites [21] Di Dalmazi, 2014, Adrenal function after adrenalectomy for subclinical hypercortisolism and Cushing’s syndrome: a systematic review of the literature, J Clin Endocrinol Metab. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
64 more claims · 7 with their cited sources checked
Create a free account to see all 101 claims and to verify the 6 references still open.
- It may state two separate claims as one. 19
- Probably not a substantial claim. 17
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Of note, among all inhaled glucocorticoids fluticasone propionate is most frequently associated with the development of symptomatic glucocorticoid-induced adrenal insufficiency and exogenous Cushing syndrome (100, 104, 107-111).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [104]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Glucocorticoid-induced adrenal insufficiency can occur with any glucocorticoid formulation (104) (Table 6) and there is no established safe level of dose exposure (24).”
From European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency (2024) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System > Materials and Methods > Data Source and Study Design
“which comprises the following 13 PTs:”
§ The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System > Materials and Methods > Data Source and Study Design
“adrenal insufficiency, adrenocortical insufficiency acute, secondary adrenocortical insufficiency, Addison’s disease, adrenal suppression, hypoaldosteronism, adrenal atrophy, steroid withdrawal syndrome, primary adrenal insufficiency, mineralocorticoid deficiency, glucocorticoid deficiency, and immune-mediated adrenal insufficiency.”
Citations
Cites
Wang, D. Y., Salem, J.-E., Cohen, J. V., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K. E., Ha, L., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.3923 · Cited by 2,674
Schneider, B. J., Naidoo, J., Santomasso, B. D., Lacchetti, C., Adkins, S., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,372
Haanen, J. B. A. G., Carbonnel, F., Robert, C., Kerr, K. M., Peters, S., Larkin, J., & Jordan, K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx225 · Cited by 2,367
Haslam, A., & Prasad, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2535 · Cited by 1,413
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Charmandari, E., Nicolaides, N. C., & Chrousos, G. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61684-0 · Cited by 644
Diagnosis and management of adrenal insufficiency
Bancos, I., Hahner, S., Tomlinson, J., & Arlt, W. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70142-1 · Cited by 467
Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis
Broersen, L. H. A., Pereira, A. M., Jørgensen, J. O. L., & Dekkers, O. M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1218 · Cited by 456
Endocrine toxicities of immune checkpoint inhibitors
Wright, J. J., Powers, A. C., & Johnson, D. B. (2021) · Nature Reviews Endocrinology · doi:10.1038/s41574-021-00484-3 · Cited by 441
Case-non-case studies: principle, methods, bias and interpretation
Faillie, J.-L. (2019) · Therapies · doi:10.1016/j.therap.2019.01.006 · Cited by 336
Cited by
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae250 · Cited by 172
Beuschlein, F., Else, T., Bancos, I., Hahner, S., Hamidi, O., van Hulsteijn, L. T., Husebye, E. S., Karavitaki, N., Prete, A., Vaidya, A., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae029 · Cited by 154
Langouche, L., Téblick, A., Gunst, J., & den Berghe, G. V. (2023) · Endocrine Reviews · doi:10.1210/endrev/bnad021 · Cited by 47
The Changing Epidemiology of Adrenal Insufficiency: Iatrogenic Factors Predominate
Rushworth, R. L., & Torpy, D. J. (2023) · Journal of the Endocrine Society · doi:10.1210/jendso/bvad017 · Cited by 29
Raschi, E., Fusaroli, M., Giunchi, V., Repaci, A., Pelusi, C., Mollica, V., Massari, F., Ardizzoni, A., Poluzzi, E., Pagotto, U., et al. (2022) · Cancers · doi:10.3390/cancers14194610 · Cited by 23
Self-citation
Metadata
- Authors
- Raschi, E., Fusaroli, M., Massari, F., Mollica, V., Repaci, A., Ardizzoni, A., Poluzzi, E., Pagotto, U., & Di Dalmazi, G.
- Affiliations
- University of Bologna (IT)
- IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
- Division of Endocrinology and Diabetes Prevention and Care Unit, IRCCS Azienda Ospedaliero–Universitaria di Bologna , Bologna 40138 , Italy
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2022-06-15
- Volume
- 107
- Issue
- 8
- Pages
- e3107-e3114
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC9282361
- OpenAlex
- W4282970174
- Cited by
- 17
- References
- 56
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 7 · 2023: 3 · 2022: 2
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nc-nd)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Pharmacology (medical) › Drug-Induced Adverse Reactions
- Keywords
- drug-induced adrenal insufficiency, adverse drug reactions, immune checkpoint inhibitors, glucocorticoids, monoclonal antibodies, disproportionality analysis, FDA Adverse Event Reporting System, pharmacovigilance, hypercortisolism, adrenocortical carcinoma, protein kinase inhibitors, hormone therapy, anti-infective agents
- MeSH terms
- Antineoplastic Agents, Immunological, Adrenal Insufficiency, Antibodies, Monoclonal, Humans, Retrospective Studies, United States, United States Food and Drug Administration, Adverse Drug Reaction Reporting Systems, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System. https://app.cochat.ai/papers/10.1210/clinem/dgac359
- The paper
- Raschi, E., Fusaroli, M., Massari, F., Mollica, V., Repaci, A., Ardizzoni, A., Poluzzi, E., Pagotto, U., & Di Dalmazi, G. (2022). The Changing Face of Drug-induced Adrenal Insufficiency in the Food and Drug Administration Adverse Event Reporting System. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgac359
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.